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Summary 26 
Background: A significant proportion of patients does not respond to, or cannot tolerate, current 27 
oral migraine preventives. Erenumab is a novel CGRP-receptor antibody with preventive 28 
efficacy in migraine. Here we assessed its efficacy and tolerability in patients with episodic 29 
migraine who had previously failed 2–4 migraine preventives (efficacy failure: no meaningful 30 
reduction in headache frequency after administration of approved preventive for migraine for at 31 
least 2-3 months based on patient history and medical judgment). 32 
Methods: LIBERTY (NCT03096834) was a 12-week, double-blind, randomised study. 33 
Participants with migraine symptoms from 4-14 days/month (28-day interval) across the three 34 
months prior to screening and during the baseline period were randomised (1:1) to receive 35 
erenumab 140 mg or placebo every four weeks subcutaneously for the 12-week double-blind 36 
treatment phase. The primary endpoint was proportion of patients achieving ≥50% reduction in 37 
monthly migraine days during Weeks 9–12. Additionally, safety and tolerability were also 38 
assessed by recording adverse events and by physical examination, vital signs, clinical laboratory 39 
assessments, and electrocardiogram. 40 
Findings: Of 246 randomised participants (n=121 for erenumab 140 mg and n=125 for placebo), 41 
240 completed the double-blind phase. Of these, 95 (38·6%), 93 (37·8%), and 56 (22·8%) had 42 
previously failed two, three, and four preventives, respectively. At Week 12, the ≥50% responder 43 
rate was observed in 36 (30·3%) patients on erenumab versus 17 (13·7%) patients on placebo 44 
(odds ratio, 95% confidence interval [CI]: 2·7 [1·4, 5·2]; p=0·002). The tolerability and safety 45 
profiles of erenumab were comparable to placebo. The most frequent treatment-emergent 46 
adverse events was injection site pain (7 [5.9%] with erenumab 140 mg, 7 [5.6%] placebo). 47 
Interpretation: Erenumab was effective in patients with episodic migraine who previously did 48 
not respond to/tolerate 2-4 migraine preventives. Erenumab might be an option for patients with 49 
difficult-to-treat migraine who have high unmet needs and limited treatment options. 50 
Funding: Novartis Pharma AG 51 
  52 
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Research in context 53 
Evidence before this study 54 
We searched PubMed to identify articles published in English language between January 1, 55 
2010, and June 18, 2018, using the search terms “episodic migraine”, “CGRP OR calcitonin 56 
gene-related peptide”, and “antibody OR antibodies”. The search retrieved 38 articles. Published 57 
literature suggests that CGRP is involved in the pathophysiology of migraine. Biologics targeting 58 
CGRP (eg. erenumab, galcanezumab, fremanezumab, eptinezumab) demonstrated efficacy in 59 
phase 2 and 3 trials of episodic migraine; however, efficacy and safety data in patients with 60 
episodic migraine who have failed multiple prior preventive treatments have not yet been 61 
published. Current oral preventive therapies for episodic migraine are associated with low-62 
adherence rates due to lack of efficacy and/or poor tolerability. Consequently, management of 63 
patients facing multiple treatment failures becomes a challenge for treating physicians. 64 
Erenumab is a fully human monoclonal antibody that inhibits the canonical CGRP receptor and 65 
has been approved in the US by the Food and Drug Administration and in Australia for the 66 
preventive treatment of migraine in adults. In phase 2 and 3 studies in chronic and episodic 67 
migraine, erenumab resulted in significant reductions in monthly migraine days and use of acute 68 
migraine medications compared to placebo. The effects on monthly migraine days were 69 
sustained for up to 15 months in an ongoing open-label extension study in episodic migraine 70 
(four to 14 headache days per month). 71 
Added value of this study 72 
LIBERTY was a 12 week, phase 3b, randomised, double-blind, placebo-controlled, multicentre, 73 
study conducted, to study the efficacy and safety of erenumab in episodic migraine patients with 74 
multiple prior treatment failures. Patients received erenumab 140 mg or placebo. At Week 12, 75 
the proportion of patients achieving ≥50% reduction in monthly migraine days from baseline 76 
(primary endpoint) was higher in erenumab as compared with placebo group. Additionally, 77 
greater reductions in monthly migraine days and days on migraine-specific medications were 78 
observed with erenumab than placebo. These results demonstrate that erenumab is a potential 79 
treatment for the management of difficult-to-treat episodic migraine patients who have 80 
previously failed multiple preventive medications. In line with previously reported experience, 81 
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tolerability and safety profiles of erenumab were comparable to placebo, and none of the patients 82 
developed binding or neutralising antibodies during the double-blind treatment phase. 83 
Implications of all the available evidence 84 
Erenumab 140 mg is a well-tolerated and potentially effective preventive treatment alternative 85 
for patients with episodic migraine, even in those who previously failed or could not tolerate 86 
multiple migraine preventives. Data from the LIBERTY Study has added to the current 87 
knowledge on erenumab as it demonstrates its additional benefit in difficult-to-treat migraine 88 
patients with high unmet needs and limited treatment options. This study will help to provide 89 
important data for clinicians treating migraine patients and to inform potential treatment 90 
algorithms. 91 
Introduction 92 
Migraine is a neurologic disease typically characterised by recurrent attacks of severe, unilateral, 93 
pulsating headache, associated with nausea, vomiting, photophobia, and phonophobia.
1
 The 94 
disease was recently ranked as the second leading cause of disability worldwide as of 2016.
2
 95 
Episodic migraine is defined as migraine on less than 15 days per month, while chronic migraine 96 
refers to patients who have migraine on 15 or more days per month for at least three months, of 97 
which at least eight days fulfil migraine criteria or have been successfully treated with migraine-98 
specific medication.
1,3
   99 
Pharmacological management of migraine includes acute and preventive treatment of attacks. 100 
Commonly used preventive treatments for episodic migraine include beta-blockers (mainly 101 
propranolol and metoprolol), anti-epileptics (mainly topiramate and valproate), anti-depressants 102 
(e.g. amitriptyline) and other treatments.
3
 None of these therapies have specifically been 103 
developed for migraine.
3-5
 Additionally, their mode of action in migraine is not clearly defined.
3,5
 104 
The efficacy and tolerability are considered to be poor (up to 50% of patients) resulting in early 105 
discontinuation of treatment.
6-9
 As a result, many patients cannot be managed with currently 106 
available preventives and consequently experience high disability and severely impaired quality 107 
of life.
2
  108 
Calcitonin gene-related peptide (CGRP) is a neuropeptide that plays an important role in 109 
migraine pathophysiology
10
 and has been shown to be a target for migraine preventive 110 
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therapies.
11,12
 Erenumab is a fully human monoclonal antibody that inhibits the canonical CGRP 111 
receptor.
13
 At 4-weekly doses of 70 mg and 140 mg, erenumab was effective in reducing 112 
monthly days with migraine and migraine-specific medications in episodic
14,15
 and chronic
16
 113 
migraine. A subset of the participants in these studies had previously failed other preventive 114 
treatments.
17
 In the present phase 3b LIBERTY study, we compared the efficacy and tolerability 115 
of erenumab versus placebo in a well-defined group of episodic migraine patients who 116 
previously had not responded adequately to 2-4 migraine preventives, or who could not tolerate 117 
these medications.  118 
Methods 119 
Study Design and Participants 120 
LIBERTY (NCT 03096834) was a 12 week, phase 3b, randomised, double-blind, placebo-121 
controlled, multicentre, parallel group study conducted from March 20, 2017 (first patient first 122 
visit) until October 27, 2017 (last patient last visit of the double blind treatment phase) at 59 sites 123 
in 16 countries across Europe and Australia (Patient enrolment summary by country provided in 124 
Supplementary Appendix 1). The study included a screening phase (0–2 weeks), baseline phase 125 
(4 weeks), double-blind treatment phase (12 weeks), open label treatment phase (156 weeks) and 126 
a follow-up phase (12 weeks). This publication reports data from the double-blind treatment 127 
phase alone. The open-label treatment phase is ongoing. 128 
The final study protocol, the informed consent form, and accompanying materials provided to 129 
study patients were reviewed and approved by an independent ethics committee or relevant 130 
institutional review board at all participating sites. This study was conducted in accordance with 131 
International Council for Harmonisation (ICH) Good Clinical Practice (GCP) 132 
regulations/guidelines. Participants provided written informed consent prior to participation. 133 
Inclusion criteria and previous preventive failures 134 
Eligible patients were aged 18–65 years and had a history of episodic migraine with or without 135 
aura
18
 for ≥12 months. They also fulfilled the ICHD3 criteria1 and had to have, migraine 136 
symptoms from 4-14 days/month (28-day interval) on average across the three months prior to 137 
screening and during the baseline period, and no more than 14 days per month headache 138 
associated/not associated with migraine.  139 
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Potential participants were: (i) to have failed preventive treatments (efficacy, tolerability, or 140 
both) with 2-4 of the following: propranolol/metoprolol, topiramate, flunarizine, 141 
valproate/divalproex, amitriptyline, venlafaxine, lisinopril, candesartan, or other locally 142 
approved preventives (cinnarizine in Czech Republic; indoramin in France; nadolol in Spain; 143 
oxetorone in France; and pizotifen in Austria, Czech Republic, France, The Netherlands, 144 
Sweden, and UK); and (ii) have failed or deemed not to be suitable for at least one out of 145 
propranolol/metoprolol, topiramate or flunarizine and (iii) have failed or deemed not suitable for 146 
valproate/divalproex.  147 
Efficacy failure was defined as no meaningful reduction in headache frequency after 148 
administration of medication for at least 2 to 3 months as recommended by the European 149 
Headache Federation treatment guidelines
19
 at generally accepted therapeutic dose(s) within the 150 
last five years prior to screening. Tolerability failure was defined as documented discontinuation 151 
due to adverse events of the respective medication at any previous time. Not suitable for the 152 
purpose of this study was defined as patient not considered suitable for treatment for medical 153 
reasons such as contraindications or precautions included in local labels, national guidelines or 154 
other locally binding documents, or other medically relevant reasons as confirmed by the treating 155 
physician. Treatment failure and unsuitability were assessed based on patient medical history and 156 
medical judgement.  157 
Exclusion criteria 158 
Patients were excluded if they were older than 50 years of age at migraine onset, pregnant or 159 
nursing, having history of cluster headache, hemiplegic migraine headache, seizure or psychiatric 160 
disorder, active chronic pain syndrome, hepatic disease, malignancy of any organ, used a 161 
preventive migraine medication within five half-lives, or a device or procedure within one month 162 
prior to the start of the baseline phase or during the baseline phase, received prior Botulinum 163 
toxin A treatment in the head/neck region within four months prior to start of the baseline phase 164 
or during the baseline phase. Patients with pre-existing myocardial infarction, stroke, transient 165 
ischemic attack, unstable angina, or coronary artery bypass surgery or other revascularisation 166 
procedures within 12 months prior to screening were excluded. Patients with medication overuse 167 
for any indication in the one month prior to the start of the baseline phase or during the baseline 168 
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phase were excluded (Complete list of inclusion and exclusion criteria are presented in 169 
Supplementary Appendix 2). 170 
Randomisation and masking  171 
Participants were randomised to placebo or erenumab 140 mg in a 1:1 ratio using the Interactive 172 
Response Technology (IRT). Randomisation was stratified by monthly migraine headache 173 
frequency: 4–7 migraine days/month versus 8–14 migraine days/month during the baseline 174 
phase. Study treatment was administered during the study visits by a study staff member not 175 
involved in the assessment of patients. Each patient received two injections of pre-filled syringe 176 
at each time point either of erenumab 70 mg/ml or placebo syringes with identical appearance. 177 
Participants, investigator staff, persons conducting various assessments and sponsor were blinded 178 
to the study treatment. 179 
Procedures 180 
During screening, participants went through a thorough medical examination, as well as 181 
eligibility assessment and training on how to use the electronic diary (eDiary) for daily reporting. 182 
During the 4-week baseline period, participants completed their eDiary daily with any 183 
headache/migraine and the rescue medication used, and the eDiary completion compliance was 184 
measured. Eligibility for randomisation was based on migraine frequency and eDiary compliance 185 
of at least ≥80% during the baseline phase. Participants received study medication at day 1 and 186 
then every four weeks for the 12-week double-blind treatment phase. The study drug, erenumab 187 
was supplied by Novartis Pharma AG and was administered as two subcutaneous injections of 188 
erenumab 70 mg/1 mL pre-filled syringe packaged individually (equalling 140 mg total dose) or 189 
matching placebo. Participants recorded the efficacy information every day using an eDiary. To 190 
aid in compliance, participants were recommended to record the information in the eDiary at the 191 
same time every day. Retroactive completion of eDiary was allowed one day prior to the time of 192 
completion but entries >2 days old were not allowed and were considered missing data. The 193 
participant reported outcome questionnaires were completed using the eDiary as per Assessment 194 
Schedule, either daily or during scheduled visit to the clinic. During the scheduled visits to the 195 
clinic, the questionnaires that were to be completed in-clinic were done before any other 196 
assessments were performed. After Day 1, at the follow-up visits at Week 4, Week 8 and Week 197 
LIBERTY-primary manuscript                                                                                                         Re-submission draft 
8 
 
12, patients were assessed for efficacy, safety and tolerability. Site staff reviewed eDiary 198 
compliance with the patient at each visit.  199 
Outcomes 200 
The primary endpoint was the proportion of patients who achieved a ≥50% reduction from their 201 
individual baseline in monthly migraine days during month three of the double-blind treatment 202 
phase. A migraine day was defined as any calendar day on which the patient had onset, 203 
continuation, or recurrence of a qualified migraine as recorded in the eDiary. A qualified 204 
migraine was defined as a migraine with or without aura lasting at least 30 minutes and 205 
manifesting with at least two headache features, at least one associated non-headache feature, or 206 
both (information on the migraine features is provided in Supplementary Appendix 3). Any 207 
calendar day on which acute migraine–specific medication was used was also counted as a 208 
migraine day.  209 
Secondary efficacy endpoints were change from baseline in monthly migraine days, change from 210 
baseline in monthly acute migraine-specific medication days including triptans or ergotamine 211 
derivatives, proportion of patients with a ≥75% or 100% reduction from baseline in monthly 212 
migraine days, change from baseline in Migraine Physical Function Impact Diary, “everyday 213 
activities-EA” and on the “physical impairment-PI”20 domains. All secondary efficacy endpoints 214 
were assessed over Month 3 (Week 9-12) of the double-blind treatment phase. Safety, 215 
tolerability, and immunogenicity were also evaluated by recording observed or reported adverse 216 
events and by physical examination, observing vital signs, clinical laboratory assessments, and 217 
electrocardiogram (ECG). 218 
Statistical Analysis 219 
Based on the observed data from a prior erenumab episodic migraine study, it was estimated that, 220 
under 2-sided 0·05 alpha level and 90% power, assuming an absolute 20%-point improvement 221 
on the response rate of the 50% reduction on monthly migraine days (primary endpoint) with an 222 
18% response rate in the placebo group (equivalent to an odds ratio [OR] of 2·8), approximately 223 
a total of 220 patients (110 per treatment group) were needed for this study. No formal interim 224 
analyses were planned during the double-blind treatment phase. No multiplicity adjustment was 225 
applied. 226 
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Statistical analysis of all data was performed using SAS
® 
statistical software (SAS Institute, 227 
Cary, NC, USA) version 9. The randomised analysis set included all randomised patients and 228 
was utilised to summarise patient disposition, demographic, baseline disease characteristics. The 229 
full analysis set included all randomised patients who started study medication and had 230 
completed at least one post-baseline monthly migraine day measurement in the double-blind 231 
treatment phase and was analysed based on the pre-planned randomised treatment; it was utilised 232 
to summarise efficacy endpoints. The safety analysis set included all randomised patients who 233 
received at least one dose of study medication and was analysed based on actual treatment 234 
received; it was utilised to summarise safety data.  235 
Demographic variables and other baseline characteristics were summarised using descriptive 236 
statistics by randomised treatment group and overall study population. The primary outcome, 237 
≥50% reduction from baseline in monthly migraine days in the last month (Month 3) of the 238 
double-blind treatment phase, was analysed using the Cochran-Mantel-Haenszel (CMH) test 239 
stratified by migraine frequency (4–7 and 8–14 monthly migraine days’ strata) used under a 240 
significance level of 0·025, one-sided (0·05, two-sided) to evaluate the association between the 241 
50% responder rate and the treatment. The estimated common OR, 95% CI and two-sided p 242 
values were reported. Patients with missing data on monthly migraine days at Month 3 of the 243 
double-blind treatment phase were imputed as non-responders. The continuous change from 244 
baseline efficacy endpoints (least square means) was analysed using a linear mixed effects model 245 
including treatment group, baseline value, stratification factor, scheduled visit, and the 246 
interaction of treatment group with scheduled visit, without any imputation for missing data. The 247 
dichotomous secondary efficacy endpoints derived from corresponding continuous endpoints 248 
were analysed using the stratified Cochran-Mantel-Haenszel (CMH) test after imputing missing 249 
data as non-response (same as the primary endpoint). Estimates (treatment difference/or OR) of 250 
erenumab compared with placebo with associated 95% CI and p-values were provided. 251 
As prior erenumab studies for prevention in episodic migraine have capped efficacy failures at 2 252 
classes, the primary and secondary efficacy endpoints in the current study were also analysed 253 
post hoc at Week 12 for the subgroups based on treatment failure of prior preventive medication 254 
(=2 vs. >2 treatment failures). For continuous variables, the interaction p-value was defined from 255 
the modified primary model with additional terms of subgroup and subgroup by treatment group 256 
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interaction as two additional effects. For the subgroup of dichotomous variables, the interaction 257 
p-value was retrieved from logistic regression that includes treatment group, stratification factor, 258 
subgroup factor and treatment by subgroup factor interaction as fixed effect with the baseline 259 
value as covariate. The adjusted mean changes from baseline, SE’s, and 95% CIs for each 260 
subgroup and the nominal p-value for subgroup by treatment interaction were calculated.  261 
For the safety analyses, the Medical Dictionary for Regulatory Activities (MedDRA) version 262 
20·1 was used to code all adverse events. Adverse events were tabulated as subject incidence and 263 
exposure-adjusted subject incidence. Summary statistics were provided for laboratory data, ECG, 264 
vital signs, and immunogenicity assessment. 265 
Role of funding source 266 
Employees of the sponsor (Novartis Pharma AG) who were involved in the design of the trial, 267 
retrieval and analyses of collected data and writing of the manuscript are included as authors of 268 
this manuscript. Study investigators showed complete collaboration and participated in each of 269 
these activities. All authors had full access to data and were responsible for their decision to 270 
submit the manuscript. All authors reviewed and approved the final version of the manuscript for 271 
submission. Institutions wishing to analyse data from the study can apply via 272 
www.clinicalstudydatarequest.com 273 
Results 274 
Patient disposition and baseline characteristics 275 
A total of 333 patients were screened for eligibility and 246 were randomised: 121 participants 276 
received erenumab 140 mg and 125 received placebo (Figure showing the study design is 277 
presented in Web Appendix). Three participants were excluded from the full analysis set and 278 
safety analysis set due to protocol deviation, as they did not receive study medication. A total of 279 
6 patients (2·4%) discontinued the double-blind treatment phase; the reasons for discontinuation 280 
were protocol deviation 3 (1·2%), pregnancy 1 (0·4%), and patient/guardian decision (one 281 
patient moved abroad and one for personal reasons, 2 [0·8%]) (Figure 1). No patient in the 282 
erenumab group discontinued treatment due to an adverse event. 283 
The treatment groups were generally well-balanced in terms of baseline demographic and disease 284 
characteristics (Table 1). At baseline, the mean (SD) monthly migraine days were 9·2 (2·6) in 285 
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the erenumab group and 9·3 (2·7) in the placebo group. Previous failure to preventives was 286 
observed in 95 (38·6%) patients for two, 93 (37·8%) patients for three, and 56 (22·8%) patients 287 
for four. The most commonly failed preventive medications were topiramate 209 (85·0%), 288 
amitriptyline 112 (45·5%) and propranolol 111 (45·1%). For most treatments, the main reason of 289 
treatment failure was lack of efficacy except for topiramate, where the main reason was lack of 290 
tolerability. A complete list of previous failed migraine preventive medication categories and 291 
discontinuation reasons and unsuitability of migraine preventive medications is provided in the 292 
Supplementary Appendix 4. 293 
Primary efficacy endpoint 294 
At 12 weeks, the ≥50% responder rate for migraine days was 36 (30·3%) for erenumab and 17 295 
(13·7%) for placebo (OR [95% CI]: 2·7 [1·4, 5·2]; p=0·002; Figure 3). Erenumab was also 296 
superior to placebo at all other time-points of assessment (Table 2; Figure 2). 297 
Secondary efficacy endpoints 298 
Erenumab was also statistically superior to placebo for all secondary endpoints (Table 2). At 299 
Week 12, participants receiving erenumab had a mean (standard error [SE]) reduction from 300 
baseline of 1·8 (0·4) days with migraine compared to 0·2 (0·4) days for placebo (mean [95% CI] 301 
difference: 1·6 [2·7, 0·5] days; p=0·004). Monthly days with specific migraine medications were 302 
reduced at Week 12 from baseline by (mean [SE]) 1·3 [0·2] for erenumab and 0·5 [0·3] for 303 
placebo (mean [95% CI] difference: 1·7 [2·4, 1·0] days; p<0·001). The ≥75% responder rates for 304 
mean migraine days were 14 (11·8%) for erenumab and 5 (4·0%) for placebo (OR [95% CI]: 3·2 305 
[1·1, 9·0]; p=0·025). The 100% responder rates were 7 (5·9%) for erenumab versus 0 (0·0%) for 306 
placebo; odds ratio could not be calculated due to zero events in the placebo group. Reductions 307 
from baseline to Week 12 were greater for erenumab versus placebo for Migraine Physical 308 
Function Impact Diary –everyday activities-EA and physical impairment-PI (for Migraine 309 
Physical Function Impact Diary –physical impairment mean difference [95% CI] 3·5 [5·7, 1·2]; 310 
p=0·003) and Migraine Physical Function Impact Diary –everyday activities (3·9 [6·1, 1·7]; 311 
p<0·001). Onset of action with erenumab and visible difference in efficacy from placebo for all 312 
the secondary outcomes was observed at the first pre-specified visit after Week 4 (Table 2). 313 
Subgroup analysis 314 
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The subgroup analyses based on treatment failure categories (=2 and >2) demonstrated 315 
improvement with erenumab 140 mg compared with placebo across the primary and secondary 316 
endpoints at Week 12. Results on the primary endpoint (50% responder rate) were comparable 317 
across patients who used common preventives (e.g. beta-blockers, topiramate and amitriptyline) 318 
and failed due to lack of efficacy or tolerability (data presented in Supplementary Appendix 5).  319 
Tolerability (and safety) 320 
All patients in both treatment groups received at least two treatments with two injections of study 321 
medication (erenumab or placebo) with the majority (>98%) having received all three treatments 322 
with a total of six injections.     323 
Overall, erenumab was well tolerated. The proportion of patients reporting at least one adverse 324 
event, serious adverse events, and adverse events leading to discontinuation of treatment were 325 
similar between the erenumab group and the placebo group (Table 3). The most frequent 326 
treatment-emergent adverse events (≥2% in the erenumab group) were injection site pain 327 
(erenumab n=7 [5·9%] vs placebo n=7 [5·6%]), back pain (erenumab n=5 [4·2%] vs placebo n=2 328 
[1·6%]), nasopharyngitis (erenumab n=5 [4·2%] vs placebo n=12 [9·7%]), and injection site 329 
erythema (erenumab n=3 [2·5%] vs placebo n=4 [3·2%]) (Table 3). The majority of adverse 330 
events observed were mild or moderate in severity. No deaths occurred during the double-blind 331 
treatment phase. Treatment-emergent serious adverse events included one case of migraine and 332 
one traumatic orbital fracture under erenumab (both not considered related to study drug) and 333 
one case of gastrointestinal infection in the placebo group. Only one patient in the placebo group 334 
developed treatment-emergent adverse events that led to discontinuation of treatment due to 335 
pregnancy. No clinically meaningful differences were observed between erenumab and placebo 336 
with regards to the results of hepatic-function testing, creatinine levels, total neutrophil counts, 337 
vital signs, or electrocardiographic findings. None of the 119 patients who received erenumab 338 
and provided testing samples, developed binding or neutralising antibodies during the double-339 
blind treatment phase.  340 
Discussion 341 
This is the first study providing evidence for preventive efficacy of a CGRP-directed therapy in 342 
episodic migraine patients with multiple prior preventive treatment failures. Nearly one-third of 343 
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patients treated with erenumab versus just over one-tenth of those with placebo showed a 344 
clinically relevant ≥50% reduction from baseline in mean monthly migraine days. Similarly, 345 
erenumab was superior to placebo for all secondary endpoints, including improvement in 346 
migraine frequency, medication use and functional outcomes. Remarkably, treatment effects 347 
were observed by the first pre-specified outcome measure at Month 1 (Week 4) after the initial 348 
dose.  349 
As with previous large placebo controlled trials in migraine prevention, the adverse event profile 350 
of erenumab was similar to placebo.
14,15
 While low levels of binding antibodies have been 351 
observed in earlier trials with longer double-blind treatment durations: 3·2% and 2·0% with the 352 
erenumab 140 mg dose without any neutralising antibodies,
15,16
  none of the erenumab-treated 353 
patients developed binding or neutralising antibodies in this study, which confirms that 354 
erenumab as a fully human antibody has a very low immunogenic potential. However, longer 355 
follow-up is needed as anti-drug antibodies could develop with long-term treatment. 356 
The results were observed in episodic migraine population with 2-4 treatment failures who are 357 
typically excluded in pivotal trials in order to avoid refractory patients and negative study 358 
outcomes. While it therefore cannot be directly compared to pivotal studies as LIBERTY 359 
includes a more difficult-to-treat population, the results from this study extend the findings from 360 
the analyses of treatment failure subgroups of earlier migraine trials with erenumab.
17,21 
In the 361 
chronic migraine pivotal study, patients with treatment failure were well represented with 453 362 
(68%) having failed at least one, 327 (49%) at least two, and 232 (35%) at least three prior 363 
preventive therapies. Erenumab, at both 70 mg and 140 mg doses was consistently more 364 
efficacious than placebo in patients with prior treatment failures (≥1, ≥2 and ≥3), with greater 365 
clinical benefit observed for the erenumab 140 mg dose. Numerically, higher therapeutic gains 366 
(higher differences from placebo) were observed with erenumab in participants who had 367 
previously failed ≥1 or ≥2 preventive medications compared with the populations with no prior 368 
treatment failure in terms of monthly migraine days and monthly acute migraine-specific 369 
medication days.
21
 This was particularly true for erenumab 140 mg, which is why the 140 mg 370 
dose was chosen for the present study. Similar findings were observed in the STRIVE study, 371 
even though the representation of prior treatment failure patients was lower with approximately 372 
369 (39%) having failed at least one and approximately 161(17%) having failed two or more 373 
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prior treatments.
17
 Erenumab showed numerically higher and nominally significant differences 374 
from placebo in the treatment failure subgroups than the respective full populations in terms of 375 
monthly migraine days and ≥50% responder rates, mainly driven by lower placebo responses.17  376 
The new results are further supported by a post-hoc analysis of the galcanezumab program that 377 
demonstrated efficacy in episodic and chronic migraine, again in patients who had failed 378 
previous preventives.
22
 Taken altogether, it seems clear that the CGRP mechanism works even in 379 
challenging patients with previous preventive failures. The absolute responses appear to be lower 380 
numerically than in less severe populations, this is partially related to the placebo behaviour in 381 
this particular patient population. 382 
Placebo response is a complex phenomenon in indications such as migraine showing some 383 
historic degree of variability, frequently depending on methodological and un-blinding issues.
23
 384 
The recent trials with erenumab
14-16
 have shown that the placebo response was higher in 385 
treatment naive patients and lower in treatment failure patients and that this was further 386 
confirmed in the LIBERTY study. Interestingly, and in line with the subgroups of patients with 387 
prior preventive treatment failure observed in those two trials, the placebo response was lower in 388 
this trial. This could possibly reflect lower expectations in patients who have tried and failed 389 
previous treatments.
24
 The overall temporal pattern of the placebo response follows the STRIVE 390 
study, in which placebo response gradually build up over the first three months and reached a 391 
plateau afterwards.
15
  392 
Study limitations 393 
A limitation of this study is that 12 weeks is not long enough to determine long-term adherence 394 
to treatment. This will be addressed in the open-label extension. The ascertainment of treatment 395 
failure status was done retrospectively, based on documented medical history conform with real-396 
world practice.  Although, patients with comorbidities, such as anxiety and depression, were 397 
allowed in the study, patients with other major comorbidities were not, which limits the 398 
generalisability of the study results to broader populations. Further, the secondary endpoints 399 
were not controlled for multiplicity and the subgroup analysis based on treatment failure 400 
categories (=2 vs >2) should be interpreted with caution due to the small sample size. 401 
Conclusions 402 
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So far, there are limited data in the treatment failure population to guide evidence-based 403 
treatment decisions for existing therapies, although what has been published suggests this 404 
outcome may not be unexpected.
25
 This study is the first direct, controlled trial evidence for a 405 
novel CGRP-directed therapy, allowing practitioners to place novel therapies in an evidence-406 
based treatment algorithm. The results suggest that erenumab might be a new treatment option 407 
for difficult-to-treat migraine patients who have previously failed traditional oral migraine 408 
preventive treatments, or who have contraindications for or could not tolerate these medications.  409 
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Tables 438 
Table 1: Key baseline and demographic characteristics of the enrolled patients, randomised set 439 
Characteristics 
Erenumab 140 mg 
(n=121) 
Placebo 
(n=125) 
Total 
(N=246) 
Age, years, mean (SD) 
 
44·6 (10·5) 
 
44·2 (10·6) 
 
44·4 (10·5) 
Gender 
Male 
Female 
 
24 (19·8) 
97 (80·2) 
 
22 (17·6) 
103 (82·4) 
 
46 (18·7) 
200 (81·3) 
Race 
Caucasian 
Non-white 
 
112 (92·6) 
9 (7·4) 
 
115 (92·0) 
10 (8·0) 
 
227 (92·3) 
19 (7·7) 
Ethnicity 
Hispanic/Latino  
Not Hispanic/Latino  
 
9 (7·4) 
104 (86·0) 
 
5 (4·0) 
109 (87·2) 
 
14 (5·7) 
213 (86·6) 
Weight, kg, mean (SD) 72·8 (14·4) 72·1 (16·2) 72·5 (15·3) 
BMI, Kg/m
2
, mean (SD) 25·0 (4·2) 24·9 (5·1) 24·9 (4·7) 
Prior migraine preventive medication failed* 
=2 
=3 
=4 
 
                  
                 43 (35·5) 
44 (36·4) 
33 (27·3) 
 
         
       52 (41·6) 
49 (39·2) 
23 (18·4) 
 
             
           95 (38·6) 
93 (37·8) 
56 (22·8) 
Prior migraine preventive medication failed 
(agents)
$
 
Amitriptyline 
Candesartan 
Flunarizine 
Lisinopril 
Metoprolol 
Propranolol 
Topiramate 
Valproate 
Venlafaxine  
Other locally approved migraine preventive 
medication 
 
49 (40·5) 
26 (21·5) 
32 (26·4) 
2 (1·7) 
46 (38·0) 
60 (49·6) 
105 (86·8) 
43 (35·5) 
6 (5·0) 
9 (7·4) 
 
63 (50·4) 
26 (20·8) 
38 (30·4) 
0 
48 (38·4) 
51 (40·8) 
104 (83·2) 
25 (20·0) 
7 (5·6) 
13(10·4) 
 
112 (45·5) 
52 (21·1) 
70 (28·5) 
2 (0·8) 
94 (38·2) 
111 (45·1) 
209 (85·0) 
68 (27·6) 
13 (5·3) 
22 (8·9) 
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Monthly migraine days, mean (SD) 9·2 (2·6) 9·3 (2·7) 9·3 (2·6) 
Aura  
Migraine with aura 
Migraine without aura 
 
42 (34·7) 
79 (65·3) 
 
45 (36·0) 
80 (64·0) 
 
87 (35·4) 
159 (64·6) 
Monthly headache days, mean (SD) 
 
10·1 (2·8) 
 
10·1 (2·7) 
 
10·1 (2·7) 
Randomisation by strata
#
 
Stratum 1: LFEM (4–7 MMD) 
Stratum 2: HFEM (8–14 MMD) 
 
36 (29·8) 
85 (70·2) 
 
38 (30·4) 
87 (69·6) 
 
74 (30·1) 
172 (69·9) 
Acute headache medication use 
Migraine specific 
Only non-migraine specific 
 
102 (84·3) 
13 (10·7) 
 
109 (87·2) 
14 (11·2) 
 
211 (85·8) 
27 (11·0) 
Monthly acute migraine-specific medication 
days, mean (SD) 
 
4·8 (2·9) 
 
4·4 (2·8) 
 
4·6 (2·9) 
Data presented as n (%) unless otherwise indicated. 
*Two patients (one in each treatment group) had a history of less than 2 prior preventive treatment failures. 
#Randomisation was stratified by low frequency EM (LFEM) vs high frequency EM (HFEM) 
$ Does not include patient not considered suitable for treatment  
BMI, body mass index; EM, episodic migraine; MMD, monthly migraine days; N, total number of patients; n, number of patients;; SD, standard deviation 
 440 
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Table 2:  Primary and secondary endpoints at Week 12 and other time-points of interest-full analysis set 
Outcome Weeks 1-4  Weeks 5-8  Weeks 9-12  
 
Erenumab 140 
mg (N=119) 
Placebo 
(N=124) 
 Erenumab 140 
mg (N=119) 
Placebo 
(N=124) 
 Erenumab 140 
mg (N=119) 
Placebo 
(N=124) 
 
 
n (%) OR (95%CI),  
p value 
n (%) OR (95%CI),  
p value 
n (%) OR (95%CI),  
p value 
Primary outcome 
≥50% responder rate& 
27 (22·7) 6 (4·8) 
 
5·9 (2·3, 14·9) 
p<0·001* 
37 (31·1) 15 (12·1) 3·3 (1·7, 6·4),  
p<0·001* 
36 (30·3 ) 17 (13·7) 2·7 (1·4, 5·2), 
p=0·002* 
Secondary outcomes          
≥75% responder rate& 
11 ( 9·2) 0 (0·0)# - 9 ( 7·6) 3 ( 2·4) 3.3 (0·9, 12·3),  
p= 0·1 
14 (11·8) 5 ( 4·0) 3·2 (1·1, 9·0), 
p=0·025 
100% responder rate& 4 ( 3·4) 0 (0·0) # - 3 ( 2·5) 0 (0·0) # - 7 ( 5·9) 0 (0·0) # - 
* Indicates statistical significance (2-sided) at 0·05 alpha level. & Responder rates reported as were observed in the week of assessment  
Statistical analysis utilises a Cochran-Mantel-Haenszel (CMH) test adjusting for stratification factor (4-7 vs. 8-14 migraine days at Baseline) after missing data are imputed as non-response (NRI). Data 
reported at Weeks 4, 8, and 12 refer to preceding four weeks #Due to zero responders (observed response rate is 0 in the placebo arm); the denominator is 0 and thus the OR cannot be computed. 
CI, confidence interval; N, number of patients included in the analysis set; n, number of patients who responded; OR, odds ratio 
 
Adjusted mean change (SE) MD (95%CI), p 
value 
Adjusted mean change (SE) MD (95%CI), p 
value 
Adjusted mean change (SE) MD (95%CI), p 
value 
Secondary outcomes 
Change from baseline in MMD 
-1·8 (0·4) 0·1 (0·3) -1·8 (-2·7, -0·9), 
p<0·001 
-2·3 (0·4) 0·1 (0·4) -2·4 (-3·4, -1·4), 
p<0·001 
-1·8 (0·4), n=118 -0·2 (0·4), 
n=120 
-1·6 (-2·7, -0·5), 
p=0·004 
Change from baseline in MSMD -1·1 (0·2) 
0·3 (0·2) -1·4 (-2·0,-0·8), 
p<0·001 
-1·3 (0·2) 0·6 (0·3) -1·9 (-2·6,-1·2), 
p<0·001 
-1·3 (0·2), n=118 0·5 (0·3), n=120 -1·7 (-2·4,-1·0), 
p<0·001 
MPFID-PI 
-2·4 (0·6) 1·3 (0·6) -3·7 (-5·3,-2·1), 
p<0·001 
-3·3 (0·6) 1·3 (0·7) -4·6 (-6·4,-2·9), 
p<0·001 
-1·9 (0·8), n=118 1·6 (0·8), n=120 -3.5 (-5·7,-1·2), 
p=0·003 
MPFID-EA 
-3·5 (0·6) 0·5 (0·6) -3.9 (-5·6,-2·3), 
p<0·001 
-4·4 (0·6) 0·5 (0·7) -4.9 (-6·7,-3·2), 
p<0·001 
-3·4 (0·8), n=118 0·6 (0·8), n=120 -3·9 (-6·1,-1·7), 
p<0·001 
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A linear mixed effects model includes treatment group, baseline value, stratification factor, scheduled visit, and the interaction of treatment group with scheduled visit. Unstructured covariance matrix 
assumed. Data reported at Weeks 4, 8, and 12 refer to preceding four weeks. 
CI, confidence interval; MMD, monthly migraine days; MPFID-EA, Migraine Physical Function Impact Diary-everyday activities; MPFID-PI, Migraine Physical Function Impact Diary-physical 
impairment; MSMD, monthly acute migraine-specific medication days; N, number of patients included in the analysis set, n, number of patients included in the model; OR, odds ratio; PBO, placebo; 
pts, patients; SE, standard error 
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Table 3:  Summary of adverse events (at least 2% TEAEs in the erenumab group)-safety analysis set 
Event 
Erenumab 140 mg 
(n=119) 
Placebo 
(n=124) 
Total 
(N=243) 
Number of patients with at least one AE 65 (54·6) 67 (54·0) 132 (54·3) 
Number of patients with any SAE 2 (1·7) 1 (0·8) 3 (1·2) 
Any AE leading to discontinuation of 
treatment 
0 1 (0·8) 1 (0·4) 
Injection site pain 7 (5·9) 7 (5·6) 14 (5·8) 
Back pain 5 (4·2) 2 (1·6) 7 (2·9) 
Nasopharyngitis 5 (4·2) 12 (9·7) 17 (7·0) 
Dizziness 3 (2·5) 2 (1·6) 5 (2·1) 
Fatigue 3 (2·5) 2 (1·6) 5 (2·1) 
Injection site erythema 3 (2·5) 4 (3·2) 7 (2·9) 
Neck pain 3 (2·5) 0 3 (1·2) 
Upper respiratory tract infection 3 (2·5) 0 3 (1·2) 
Data reported as n (%). 
A subject with multiple AEs is counted only once in the “at least one AE” row. 
A subject with multiple AEs with the same preferred term is counted only once for that preferred term. 
AE, adverse event, SAE, serious adverse event, TEAE, treatment emergent adverse events 
Figure legends 
Figure 1: Trial profile 
Figure 2: Proportion of patients with ≥50 reduction in monthly migraine days (primary endpoint) 
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